

NCI SBIR AND YOUR STATE:

PENNSYLVANIA



Between FY1998 and FY2010, the NCI SBIR Development Center awarded **\$32.3 million** in funding across **25 Phase II SBIR/STTR grants** to small businesses in Pennsylvania. The following economic impact estimates quantify the program's contributions to the state's economy:



\$443M

IN TOTAL DIRECT SALES



\$1.3B

IN TOTAL ECONOMIC IMPACT



5.4K

JOBS CREATED



\$44.7M

IN STATE & LOCAL TAXES COLLECTED



15

COMPANIES WITH SALES

**These state-specific figures are derived from the 2018 NCI SBIR/STTR Economic Impact Study analysis, which assessed the impact of Phase II grant awards initiated from FY1998-FY2010 and the economic results of these investments up to 2018. NCI continues to provide SBIR/STTR grant awards in Pennsylvania: between FY1998 and FY2024, the NCI SBIR Development Center distributed \$134.9M in funding across all grants to oncology-focused small businesses in the state.*

Success stories include: **ONCOCEUTICS, INC.**

Oncoceutics used SBIR funding to develop ONC201 (Modeyso), a drug to treat brain tumors in pediatric and adult patients. Chimerix acquired Oncoceutics for \$438 million in January 2021 and the drug received FDA accelerated approval in August 2025.

QUANTITATIVE RADIOLOGY SOLUTIONS, LLC

NCI SBIR supported the UPenn spinout's Automatic Anatomy Recognition (AAR) System clinical trial evaluation that was the basis for its 510k approval in April 2021. The technology aims to increase the accuracy of radiation treatment planning, while increasing planning productivity by 20 - 30%.

The NCI SBIR Development Center offers information sessions on funding opportunities and resources for cancer technology startups. If your state is interested in hosting, please reach out to ncisbir@mail.nih.gov.